Skip to main content
China Resources Pharmaceutical Group Limited logo

China Resources Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 3320 ISIN · HK0000311099 LEI · 3003004H1KDKMJ8JD874 HKEX Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2023-11-27 Capital/Financing Update
Country HK Hong Kong
Listing HKEX 3320

About China Resources Pharmaceutical Group Limited

http://www.crpharm.com

China Resources Pharmaceutical Group Limited operates an integrated pharmaceutical value chain encompassing research and development, manufacturing, distribution, and retail of medicines and healthcare products. As an investment holding company, it manages a diverse portfolio focused primarily on the domestic market. Its manufacturing capabilities span multiple therapeutic areas, including chemical drugs, biological drugs, natural medicine, and traditional Chinese medicine. The group leverages its extensive distribution network and retail operations to ensure broad market coverage across China.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION UPDATE ON THE POTENTIAL ISSUANCE OF SHARES BY CR PHARMACEUTICAL COMMERCIAL
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a potential issuance of shares by a subsidiary company, China Resources Pharmaceutical Commercial. It details the commencement of a bidding process for this potential issuance, the terms of the issuance, and the intended use of proceeds. The document references regulatory rules (Listing Rules and Securities and Futures Ordinance) and provides cautionary advice to investors. It does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or presentation. The content focuses on capital raising activities and updates on financing plans. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about the financing activity, not merely an announcement of a report publication or a regulatory filing. Hence, the classification is CAP with high confidence.
2023-11-27 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 October 2023. It details movements in issued shares, share options, and confirms no changes in authorized share capital or other share-related movements. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, focusing on share capital and share movements. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to share capital movements and compliance with listing rules. The document length is about 5,068 characters, which is consistent with a detailed regulatory filing rather than a brief announcement or a full annual/interim report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-11-01 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL HOLDINGS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023 IN RELATION TO THE ISSUANCE OF MEDIUM TERM NOTES AND CORPORATE BONDS IN THE PRC
Interim / Quarterly Report Classification · 95% confidence The document is an announcement by China Resources Pharmaceutical Holdings regarding its unaudited financial results for the nine months ended 30 September 2023. It includes detailed financial statements such as balance sheet, profit or loss statement, and cash flow statement prepared according to PRC GAAP. The document is not merely an announcement of a report but contains substantive financial data and analysis for a period shorter than a full fiscal year (nine months). It is unaudited and explicitly described as quarterly financial information related to issuance of medium term notes and corporate bonds. This fits the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial statements, not just a summary or announcement. Therefore, the appropriate classification is IR with high confidence. 9M 2023
2023-10-31 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF DONG-E-E-JIAO FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
Regulatory Filings Classification · 95% confidence The document is an announcement of unaudited financial results for the nine months ended 30 September 2023 of Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Limited. It provides key financial figures but explicitly states that the financials are unaudited and that the full quarterly report is published on the Shenzhen Stock Exchange website. The document length is 3714 characters, which is relatively short and mainly serves to announce the availability of the quarterly report rather than presenting a comprehensive financial report itself. According to the 'Menu vs Meal' rule, such announcements that refer to a report published elsewhere and are short in length should be classified as Regulatory Filings (RNS) rather than as the actual Interim/Quarterly Report (IR). Therefore, this document is best classified as a Regulatory Filing (RNS).
2023-10-30 English
INSIDE INFORMATION POTENTIAL ISSUANCE OF SHARES BY CR PHARMACEUTICAL COMMERCIAL
Capital/Financing Update Classification · 95% confidence The document is an announcement made pursuant to the Listing Rules of the Hong Kong Stock Exchange and the Securities and Futures Ordinance. It discusses a potential issuance of new shares by a subsidiary of the company via a public bidding process. The announcement clarifies that no binding agreement has been entered into yet and that the issuance is subject to further processes and approvals. The document is relatively short (4397 characters) and serves to inform the market about a potential capital raising event rather than providing detailed financial data or results. It does not contain financial statements or detailed analysis but is an update on financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-10-30 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF KPC FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
Regulatory Filings Classification · 95% confidence The document is an announcement of unaudited financial results for the nine months ended 30 September 2023 for KPC Pharmaceuticals, a subsidiary of the company. It provides key financial figures but explicitly states that the financials are unaudited and that the full quarterly report is published on the Shanghai Stock Exchange website. The document length is 3425 characters, which is relatively short and mainly serves as a summary or announcement rather than a full financial report. It does not contain detailed financial statements or substantive analysis itself, but rather points to the full quarterly report elsewhere. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an announcement of financial results without the full report content, and it is not a full Interim/Quarterly Report (IR).
2023-10-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.